|
|
|
|
|
|
This article may be reprinted free of charge provided 1) that there is clear attribution to the Orthomolecular Medicine News Service, and 2) that both the OMNS free subscription link http://orthomolecular.org/subscribe.html and also the OMNS archive link http://orthomolecular.org/resources/omns/index.shtml are included. FOR IMMEDIATE RELEASE
Commemorating the Centennial of the Warburg Effect with a Visionary Proposal
Richard Z. Cheng, M.D., Ph.D.The recent publication titled "Clinical Research Framework Proposal for Ketogenic Metabolic Therapy in Glioblastoma" in BMC Medicine is a fitting tribute to the centennial of Otto Warburg’s groundbreaking discovery (1). In commemoration of the 100th anniversary of the Warburg Effect, an international team of metabolic cancer therapy experts, led by Dr. Thomas N. Seyfried —and of which I am honored to be a member—has developed this landmark proposal. The study seeks to redefine the treatment paradigm for glioblastoma through the innovative application of ketogenic metabolic therapy. This study presents a visionary clinical research framework, integrating a century of insights into cancer metabolism. It explores how ketogenic metabolic therapy (KMT) can exploit the metabolic vulnerabilities of glioblastoma cells—particularly their dependence on substrate-level phosphorylation (SLP, via glycolysis), as elucidated by the Warburg Effect. By depriving tumor cells of their preferred energy source (glucose and glutamine) while providing alternative fuels that healthy cells can utilize more efficiently (e.g., ketones), KMT offers a novel, less toxic therapeutic approach. Dr. Seyfried’s leadership has been instrumental in extending the legacy of the Warburg Effect. His pioneering work emphasizes the metabolic underpinnings of cancer and challenges the traditional gene mutation-centric model. By framing glioblastoma as primarily a metabolic disease driven by mitochondrial dysfunction, this proposal lays the groundwork for innovative clinical trials designed to evaluate the efficacy of metabolic therapies in improving survival and quality of life for patients with this aggressive brain tumor. The publication of this proposal not only celebrates a century of progress since Warburg’s discovery but also charts a course for the future of cancer treatment. It underscores the importance of collaborative, forward-thinking research to harness the therapeutic potential of metabolic strategies in the fight against glioblastoma and other malignancies. The framework described in this paper extends well beyond glioblastoma. According to the metabolic theory of cancer (2), the fundamental biology of all cancers stems from a mitochondrial energy metabolism deficiency (respiratory insufficiency leading to SLP dependency), a hallmark shared across diverse tumor types. By addressing the metabolic vulnerabilities of cancer cells through ketogenic metabolic therapy, this framework offers a versatile model that can be adapted to study and treat various cancers, with the potential to improve outcomes across a broad range of malignancies. Clinical Research Framework Proposal for Ketogenic Metabolic Therapy in GlioblastomaGlioblastoma (GBM) is an aggressive brain tumor with limited treatment options and poor prognosis. Recent research has explored the potential of ketogenic metabolic therapy (KMT) as an adjunct to standard treatments. KMT involves high-fat, low-carbohydrate diets and fasting to shift the body's metabolism towards fat utilization and ketone production (oxidative metabolites), potentially exploiting the metabolic vulnerabilities of cancer cells. This study proposes a comprehensive clinical research framework to evaluate the efficacy and safety of KMT in GBM patients. The framework includes:
The authors emphasize the importance of multidisciplinary collaboration and standardized protocols to ensure the reliability and reproducibility of results. They also highlight the need for personalized approaches, considering individual patient metabolism and tumor biology. By providing this structured framework, the study aims to guide future clinical trials investigating KMT in GBM, with the ultimate goal of improving patient outcomes through innovative metabolic interventions. References1. Duraj, T., Kalamian, M., Zuccoli, G. et al. Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma. BMC Med 22, 578 (2024). https://doi.org/10.1186/s12916-024-03775-4 2. https://www.amazon.com/Cancer-Metabolic-Disease-Management-Prevention/dp/0470584920 Nutritional Medicine is Orthomolecular MedicineOrthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org Find a DoctorTo locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource. Editorial Review Board:
Albert G. B. Amoa, MB.Ch.B, Ph.D. (Ghana)
Comments and media contact: editor@orthomolecular.org OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication. To Subscribe at no charge: http://www.orthomolecular.org/subscribe.html To Unsubscribe from this list: http://www.orthomolecular.org/unsubscribe.html |
This website is managed by Riordan Clinic
A Non-profit 501(c)(3) Medical, Research and Educational Organization
3100 North Hillside Avenue, Wichita, KS 67219 USA
Phone: 316-682-3100; Fax: 316-682-5054
© (Riordan Clinic) 2004 - 2024c
Information on Orthomolecular.org is provided for educational purposes only. It is not intended as medical advice.
Consult your orthomolecular health care professional for individual guidance on specific health problems.